Medical expert video library
MORE PERSPECTIVES
Dr Mabel Mardones explains why she chooses KISQALI + AI or fulvestrant
Watch as she shares her personal insights on treating her patients with HR+/HER2- mBC at her practice in Colorado.
Dr Mardones has been compensated for her time by Novartis Pharmaceuticals Corporation.
AI, aromatase inhibitor; HER2-, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive; mBC, metastatic breast cancer.
Dr Jules Cohen discusses why he chooses KISQALI as his preferred CDK4/6 inhibitor
Watch as he shares his perspective on treating patients with HR+/HER2- mBC at his practice in New York.
Dr Cohen has been compensated for his time by Novartis Pharmaceuticals Corporation.
CDK, cyclin-dependent kinase; HER2-, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive; mBC, metastatic breast cancer.
Dr Mabel Mardones and Dr Jules Cohen discuss the significance of the MONALEESA-7 trial
Watch as they discuss, in their own words, the overall survival data from the MONALEESA-7 trial and how they use KISQALI for their premenopausal patients with HR+/HER2- mBC.
Drs Mardones and Cohen have been compensated for their time by Novartis Pharmaceuticals Corporation.
HER2-, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive; mBC, metastatic breast cancer.
NCCN GUIDELINES®
An expert discusses the National Comprehensive Cancer Network® (NCCN®) Category 1 Preferred 1L treatment options
There is controversy on the choice of CDK4/6i as there are no head-to-head comparisons between the agents and there are some differences in the study populations in the phase III randomized studies.
NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
Dr Cohen has been compensated for his time by Novartis Pharmaceuticals Corporation.
1L, first line; CDK4/6i, cyclin-dependent kinase 4/6 inhibitor.
EFFICACY & SAFETY
An expert discusses proven overall survival across 3 phase III trials in patients with HR+/HER2- mBC
Dr Gabriel Hortobagyi discusses proven overall survival with KISQALI across 3 phase III trials.
Dr Hortobagyi has been compensated for his time by Novartis Pharmaceuticals Corporation.
START & STAY
Expert perspective on dosing and patient adherence in HR+/HER2- mBC
Dr Nick McAndrew shares his perspective on simple dose reductions with KISQALI + AI or fulvestrant and how to improve adherence in patients with HR+/HER2- mBC.
Dr McAndrew has been compensated for his time by Novartis Pharmaceuticals Corporation.
ROUND TABLE
Round table discussion: Managing QT interval and ECG assessments
Drs Dent, Guha, and Moore discuss a hypothetical premenopausal patient with HR+/HER2- mBC. The team discusses managing QT interval and ECG assessments when starting patients on KISQALI in combination with AI or fulvestrant, as well as managing them throughout treatment.
Drs Dent, Guha, and Moore have been compensated for their time by Novartis Pharmaceuticals Corporation.
Round table discussion: Addressing DDIs
Drs Dent, Guha, and Moore discuss a hypothetical postmenopausal patient with HR+/HER2- mBC. The team addresses potential drug-drug interactions with medications the patient is currently taking to manage other conditions.
Drs Dent, Guha, and Moore have been compensated for their time by Novartis Pharmaceuticals Corporation.
Round table discussion: Addressing cardiac comorbidities
Drs Dent, Guha, and Moore discuss a hypothetical postmenopausal patient with HR+/HER2- mBC with preexisting cardiac conditions, how these may factor into her treatments, and the best method for starting treatment with KISQALI in combination with AI or fulvestrant.
Drs Dent, Guha, and Moore have been compensated for their time by Novartis Pharmaceuticals Corporation.
DDI, drug-drug interaction; ECG, electrocardiogram.